Rationale: Mobile stroke units speed treatment for acute ischemic stroke, thereby possibly improving outcomes.
Introduction and rationale
Earlier treatment with tissue plasminogen activator (tPA) and intra-arterial thrombectomy (IAT) results in better outcome. 1, 2 Mobile stroke units (MSUs), ambulances with a computed tomography (CT) scanner; point-ofcare laboratory; and stroke team speed evaluation, triage, and treatment within the first hour after time last seen normal (LSN) 3 -a metric difficult to achieve with standard management (SM). A nonrandomized analysis suggested improved functional outcomes. 4 We hypothesize that faster and more accurate stroke diagnosis and treatment with MSU implementation will result in better outcomes and be more cost effective in tPA-eligible acute ischemic stroke patients calling 911. The cost-effectiveness analysis (CEA) will consider both poststroke healthcare utilization and fixed costs of introducing and operating an MSU. The CEA will assess whether long-term cost savings are achieved thereby providing justification for higher reimbursement to providers.
Study design
The ongoing Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit (BEST-MSU) trial is a prospective cluster-randomized comparative effectiveness study of two prehospital strategies for managing stroke patients: earlier diagnosis and treatment using an MSU versus standard triage and transport by Emergency Medical Services (EMS). The Institutional Review Board approved this study.
Participants
Participants who call 911 within the hours of BEST-MSU study operation are considered for enrollment. The criteria for alerting the MSU team, enrolling the patient, and tPA eligibility are detailed in Table 1 . Analyses comparing the primary clinical outcomes and the cost analyses will only be performed on tPA-eligible patients, irrespective of tPA receipt, based on intentionto-treat criteria. iv. Informed consent obtained from patient or legal representative. Prehospital management and treatment, including IV tPA, not delayed for consent; consent must eventually be obtained for data to be retained for analysis.
3. Criteria for tPA eligibility (to be confirmed and finally determined by blinded adjudicator) i. Meeting inclusion/exclusion criteria according to current AHA guidelines. 
Data collected
Patient data are collected on case report forms and entered into a centralized electronic database (OpenClinica). Data collection is summarized in Supplemental Table. Cluster randomization
Patients are enrolled into MSU versus SM weeks depending on when their stroke occurs.
Blinding and limiting bias
All patients are screened for trial enrollment during their prehospital evaluation and management by the same investigators on both MSU and SM weeks to ensure that comparisons are made between similar patients, using similar criteria, at a similar stage of illness. For enrolled patients, criteria for study enrollment and tPA treatment are subsequently reviewed by a vascular neurologist (VN) blinded to MSU versus SM assignment and not otherwise involved in study management or analysis. The blinded VN determines from a dedicated ''adjudication form,'' omitting any time data or other information that would produce unblinding, if the patient meets criteria for study enrollment and for tPA treatment. For comparing outcomes between MSU and SM, we will only include tPA-eligible patients on both MSU and SM weeks, whether or not actually treated, based on this blinded review. Investigators obtaining all outcomes are blinded to treatment allocation.
Study interventions
Hours of MSU study operations are the same on MSU and SM weeks. On MSU weeks, the MSU is staffed by a paramedic, certified CT technologist, research nurse (RN), and a VN either an on-board or via telemedicine (TM). 5 After alert by EMS (Table 1) , the MSU is dispatched and once on scene (e.g. the patient's home, workplace, etc.), the patient is jointly evaluated by the EMS squad and MSU team. If the patient meets criteria for enrollment (Table 1) , they are moved into the MSU. Otherwise, they are transported by EMS.
Inside the MSU, blood samples are analyzed, the CT tech performs a noncontrast head CT, uploads the data for immediate visualization on the MSU laptop, and transmits images via a DICOM grid to the receiving facility. After reviewing the CT, the VN completes their evaluation including NIH Stroke Scale (NIHSS) and decides whether the patient qualifies for tPA according to published guidelines. 6 The tPA bolus is given without delay followed by the infusion. A CT angiogram may then be done to help triage the patient for IAT. After the tPA decision, the patient is transported in the MSU to the appropriate participating comprehensive stroke center or primary stroke center according to standard EMS policy.
Patients receive standard post-tPA management. The destination hospital/stroke team are prenotified, and all further care carried out at the destination ED according to their usual routine. The MSU team obtains consent and records study-related data.
On SM weeks, the MSU is alerted in the same way as in MSU weeks but not dispatched, and the MSU RN or VN meets the patient and EMS squad at the destination ED (which has been selected and prenotified as on MSU weeks). They obtain the patient's history and NIHSS without delaying the ED intake process. If the patient meets all inclusion/exclusion criteria except lab and CT (which have not yet been done), the patient is enrolled into the SM arm. Baseline comparability of MSU versus SM patients is carefully monitored by the Study Monitoring Committee, and any numerical imbalance factored into the sample size calculation.
If the baseline labs and CT scan obtained after the patient reaches the ED do not then exclude the patient, then the patient is considered a ''SM tPA-eligible patient,'' whether or not they eventually receive tPA in the ED (i.e. the 4.5 h time window might elapse, or the patient's deficit might resolve, by the time the patient is fully evaluated in the ED).
The hospital-based stroke team manages the patient, including whether to give tPA, per their routine. For all SM enrolled patients, the MSU team obtains consent and records study-related data.
If the MSU is busy transporting while another call comes in and if the team can respond and get to the ED while EMS is still there, the patient is considered to be enrolled under SM. Otherwise, those calls are not included in the study.
Follow-up data collection
Resource utilization forms (RUFs) capture utilization associated with managing the stroke event as well as poststroke. RUFs are collected at baseline, discharge, third, sixth, ninth, and 12th month. 7 The RUFs obtain inpatient (hospital, skilled nursing, inpatient rehabilitation, nursing home, long-term acute care, and hospice stays), emergency department, ambulance service, outpatient (including physician office and therapist visits), home healthcare, durable medical equipment, and pharmacy utilizations. Quality of life (QoL) using the EQ-5D instrument is also collected every three months.
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Outcome measures
The primary outcome is the utility-weighted modified Rankin scale (uw-mRS) at 90 days in patients meeting criteria for tPA treatment. The utility weights transform the seven levels of the mRS to values between 0 and 1 with distances between the levels reflecting patient and societal valuation of each disability state. 8 The uw-mRS provides two advantages over the dichotomized mRS and shift approach: (a) dichotomizing an ordinal outcome results in loss of information whereas the use of the uw-mRS provides a way to use all points in the scale in a clinically and patient-centered way-this is important especially since at least 20% of the study's patients start with a mRS of 2 or greater at baseline and so cannot achieve a mRS < 2 if we used a dichotomized outcome, and (b) compared to the shift analysis, the uw-mRS provides a patient-centered weighting of the outcome where the difference between a mRS of 3 and 4 (the ability to walk independently or not) and between a mRS of 0 and 1 (no versus some symptoms but no observable neurologic deficit) are both a one-point difference but generally not considered to be the same difference for patients-the uw-mRS estimates the relative difference between categories. The coprimary outcome is cost-effectiveness based on two measures: (1) cost: sum total of all utilizations measured through the RUFs weighted with Medicare reimbursement amounts and (2) effectiveness/utility: quality-adjusted life years obtained from conversion of the EQ-5D's QoL information.
Secondary outcomes include (1) 90-day mRS; (2) time metrics including LSN, alert, scene arrival and departure, tPA decision, tPA bolus, ED arrival, and start of IAT; (3) healthcare utilization during the first year after the stroke; (4) QoL. Safety outcomes include mortality and symptomatic hemorrhage.
Statistical analyses
Chi-square and Wilcoxon rank sum tests will evaluate baseline differences between the arms for categorical and continuous variables, respectively. Variables with baseline differences will be included in adjusted analyses. Completers will be compared to those lost to follow-up (LTF) to indicate whether missingness is random.
Clinical primary outcome analysis. The mean uw-mRS at 90 d along with corresponding two-sided 95% confidence intervals will be compared between groups using a two-sample t-test or Wilcoxon rank sum test if the assumption of normality does not hold. Although the mRS is an ordinal outcome, the difference between the uw-mRS categories has clinical significance and the t-test assumption and central limit theorem are likely satisfied. The analyses of uw-mRS will be adjusted for baseline uw-mRS, any baseline covariates that are different between the groups, and covariates associated with mRS, including baseline NIHSS, age, premorbid mRS, and previous TIA/stroke, in a linear regression model. Sensitivity analyses of the primary outcome will be conducted including ordinal (shift) analysis of mRS using a proportional odds model and proportion achieving a dichotomized outcome of mRS 0-1 versus 2-6 using logistic regression. Secondary analyses will include comparing outcomes in patients treated with tPA within 60 min of LSN to similar patients treated later.
Heterogeneity of treatment effects. Estimates of MSU effect will be obtained for prespecified subgroups with significant treatment-by-subgroup interactions including patients (1) treated via TM versus on-site VN, (2) treated at various sites, (3) receiving IAT, and (4) with and without baseline disability. Any subgroup analyses not prespecified will be considered post hoc and requiring confirmation in future studies.
Sample size justification. The power of this trial was based on the difference in primary outcome, 90-day uw-mRS. Based on preliminary data, we expected 1.8 times as many MSU as SM patients because when we began the study, on SM weeks some patients were occasionally taken by EMS to nonparticipating stroke centers where they could not be enrolled into the study. On MSU weeks, these patients would be transported in the MSU only to participating hospitals and therefore enrolled. Subsequently, we have incorporated these nonparticipating hospitals into the study, thereby mitigating this gap and the groups are now balanced. With a sample size of 693 total tPA-eligible patients (446 MSU and 247 SM patients, assuming 10% LTF), the study will have 80% power with a 0.05 type I error to detect a difference between groups of 0.09 in the mean uw-mRS using a two-sample t-test. This difference is plausible and important. In a reanalysis of 11 acute stroke studies, 8 the difference in mean 90 d uw-mRS between groups ranged from 0.024 to 0.25, with most positive trials in the range of 0.1. In the NINDS tPA trial, 90-day uw-mRS difference was 0.09 between tPA and placebo. 8 After adding previously nonparticipating stroke centers, we observed a more balanced ratio between MSU and SM groups (overall imbalance is expected to be less than 1.7). Additionally, blinded to study data but based on subsequently published data from Berlin, 4 we revised the target sample size to 984 total tPA-eligible patients (620 MSU and 364 SM, assuming 10% LTF), giving the study 80% power with a 0.05 type I error to detect a difference between International Journal of Stroke, 13 (3) groups of 0.075 in the mean uw-mRS using a twosample t-test.
Interim analyses. Interim analyses for safety (symptomatic hemorrhage), efficacy/futility (dichotomized mRS 0-1 versus 2-6; O'Brien-Fleming boundary with Lan-DeMets alpha spending function 9, 10 ), and process (time from alarm until treatment decision) will be conducted when the 90-day mRS has been collected on 50% of the target total number of patients adjudicated to be tPA eligible. International Journal of Stroke, 13 (3) Economic evaluation. First year and lifetime CEA will be performed from Medicare's perspective using the incremental cost-effectiveness ratio (ICER) and the net benefit regression (NBR) methods. The CEA will be reported separately from the primary clinical and secondary outcomes. Lifetime costs after the first year will be simulated using Markov modeling. 11, 12 The 95% confidence interval for the ICER will assess uncertainty through nonparametric bootstrapping. 13 If the ICER replicates estimated during bootstrapping cover more than one quadrant of the cost-effectiveness plane, the cost-effectiveness acceptability curve approach will be used to capture uncertainty.
14 Deterministic one-way and multiway sensitivity analyses will determine the robustness of the ICER and NBR estimates by varying the study parameters by set percentage points in each direction, determined thorough literature review and expert opinion. (1) Rehospitalizations; (2) other inpatient stays; (3) emergency department visits; (4) QoL; and (5) survival will be compared between groups using logistic regression, linear regression, and survival analysis.
Study organization/monitoring
The BEST-MSU study has a Clinical Coordinating Center (Dr Grotta, PI) and Data Coordinating Center (Dr Yamal, Co-PI). A Steering Committee oversees the study and reports to an independent Study Monitoring Committee (SMC) which meets twice yearly to review group data and study progress especially at the local site. Only Dr Yamal and the SMC are unblinded to group data. Each site has a Patient/ Stakeholder Advisory Subcommittee, comprised of four EMS and four rotating patient representatives, to provide advice/feedback. 
Current status of the trial

Conclusion
This is the first prospective randomized multicenter study to compare disability and healthcare utilization with MSU versus SM and to examine cost-effectiveness. Due to the unblinded intervention, the BEST-MSU study has many unique challenges regarding the comparability of the study arms. We have incorporated several innovative approaches in our study design to address these challenges. First, both SM and MSU patient enrollment and tPA eligibility are assessed by the same investigators and based on the time and clinical stroke severity at the time of EMS arrival and not at ED arrival. Second, we use blinded adjudication process to determine the sample for the primary analysis. Third, outcomes are blindly assessed.
As a pragmatic trial, we have aimed to make MSU and SM patient enrollment methods as comparable as possible while at the same time maximizing enrollment of eligible patients. We do not think that the differences in number of patients enrolled on MSU versus SM weeks will result in qualitative differences between patients in the two groups or how they are managed after hospital arrival. Furthermore, any important imbalances would be addressed by the SMC who reviews comparability of the groups every six months. To date, the SMC has not identified any concerns regarding the study arm comparability.
We have developed an innovative randomization, blinded adjudication, and study enrollment process to address the distinct challenges of this study.
